CA2652981C - Robust sustained release formulations - Google Patents
Robust sustained release formulations Download PDFInfo
- Publication number
- CA2652981C CA2652981C CA2652981A CA2652981A CA2652981C CA 2652981 C CA2652981 C CA 2652981C CA 2652981 A CA2652981 A CA 2652981A CA 2652981 A CA2652981 A CA 2652981A CA 2652981 C CA2652981 C CA 2652981C
- Authority
- CA
- Canada
- Prior art keywords
- sustained release
- ethanol
- oxymorphone
- formulation
- robust
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Addiction (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2006/039923 WO2008045060A1 (en) | 2006-10-10 | 2006-10-10 | Robust sustained release formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2652981A1 CA2652981A1 (en) | 2008-04-17 |
CA2652981C true CA2652981C (en) | 2012-05-01 |
Family
ID=38048029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2652981A Expired - Fee Related CA2652981C (en) | 2006-10-10 | 2006-10-10 | Robust sustained release formulations |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2079453A1 (pt) |
JP (1) | JP5422388B2 (pt) |
KR (1) | KR20090113243A (pt) |
CN (1) | CN101578096A (pt) |
AU (1) | AU2006349402A1 (pt) |
BR (1) | BRPI0621947A2 (pt) |
CA (1) | CA2652981C (pt) |
IL (1) | IL198168A0 (pt) |
MX (1) | MX2009003771A (pt) |
WO (1) | WO2008045060A1 (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1268338C (zh) | 2001-07-06 | 2006-08-09 | 恩德制药公司 | 用作止痛剂的6-羟基羟吗啡酮的口服给药 |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
BR112012001244A2 (pt) | 2009-07-22 | 2020-12-08 | Gruünenthal Gmbh | Forma de dosagem resitente à adulteração, seu processo de produção, e embalagem contendo tal forma |
RU2604676C2 (ru) | 2010-09-02 | 2016-12-10 | Грюненталь Гмбх | Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль |
PT2736497T (pt) | 2011-07-29 | 2017-11-30 | Gruenenthal Gmbh | Comprimido resistente a adulteração proporcionando libertação imediata de fármaco |
BR112014002022A2 (pt) | 2011-07-29 | 2017-02-21 | Gruenenthal Gmbh | comprimido resistente à violação proporcionando liberação de fármaco imediata |
AR090245A1 (es) | 2012-03-06 | 2014-10-29 | Otsuka Pharma Co Ltd | Preparacion solida oral de liberacion sostenida, metodo de preparacion |
ES2692944T3 (es) | 2012-04-18 | 2018-12-05 | Grünenthal GmbH | Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis |
US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
CN105934241B (zh) | 2013-11-26 | 2020-06-05 | 格吕伦塔尔有限公司 | 通过低温研磨制备粉末状药物组合物 |
AU2015266117A1 (en) * | 2014-05-26 | 2016-11-24 | Grunenthal Gmbh | Multiparticles safeguarded against ethanolic dose-dumping |
CN104622791A (zh) * | 2015-02-13 | 2015-05-20 | 扬子江药业集团有限公司 | 地佐辛口服制剂 |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
US20170296476A1 (en) * | 2016-04-15 | 2017-10-19 | Grünenthal GmbH | Modified release abuse deterrent dosage forms |
KR102380498B1 (ko) * | 2021-02-24 | 2022-04-01 | 주식회사 청안오가닉스 | 건강기능식품에 있어서 유효성분의 지속적인 방출을 제어할 수 있는 서방형 정제를 제조하기 위한 조성물 |
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4994276A (en) * | 1988-09-19 | 1991-02-19 | Edward Mendell Co., Inc. | Directly compressible sustained release excipient |
US5169639A (en) * | 1988-09-19 | 1992-12-08 | Edward Mendell Co., Inc. | Controlled release verapamil tablets |
US5773025A (en) * | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
FR2729857B1 (fr) * | 1995-01-27 | 1997-04-04 | Rhone Poulenc Chimie | Compositions pharmaceutiques sous forme de comprimes a liberation prolongee a base de granules en polysaccharides de haut poids moleculaire |
US5904937A (en) * | 1997-10-03 | 1999-05-18 | Fmc Corporation | Taste masked pharmaceutical compositions |
ITMI20000788A1 (it) * | 1999-04-13 | 2001-10-11 | Beecham Pharmaceuticals Pte Li | Nuovo metodo di trattamento |
US20030118641A1 (en) * | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
EP1404332A1 (en) * | 2001-07-06 | 2004-04-07 | Penwest Pharmaceuticals Company | Methods of making sustained release formulations of oxymorphone related applications |
CN1268338C (zh) * | 2001-07-06 | 2006-08-09 | 恩德制药公司 | 用作止痛剂的6-羟基羟吗啡酮的口服给药 |
CA2459976A1 (en) * | 2001-09-26 | 2003-04-03 | Penwest Pharmaceuticals Company | Opioid formulations having reduced potential for abuse |
US20060193912A1 (en) * | 2005-02-28 | 2006-08-31 | Penwest Pharmaceuticals Co. | Controlled release O-desmethylvenlafaxine formulations |
-
2006
- 2006-10-10 EP EP06825846A patent/EP2079453A1/en not_active Withdrawn
- 2006-10-10 AU AU2006349402A patent/AU2006349402A1/en not_active Abandoned
- 2006-10-10 CN CNA2006800560384A patent/CN101578096A/zh active Pending
- 2006-10-10 JP JP2009532331A patent/JP5422388B2/ja not_active Expired - Fee Related
- 2006-10-10 BR BRPI0621947-0A patent/BRPI0621947A2/pt not_active IP Right Cessation
- 2006-10-10 KR KR1020097007890A patent/KR20090113243A/ko not_active Application Discontinuation
- 2006-10-10 CA CA2652981A patent/CA2652981C/en not_active Expired - Fee Related
- 2006-10-10 WO PCT/US2006/039923 patent/WO2008045060A1/en active Application Filing
- 2006-10-10 MX MX2009003771A patent/MX2009003771A/es unknown
-
2009
- 2009-04-16 IL IL198168A patent/IL198168A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN101578096A (zh) | 2009-11-11 |
EP2079453A1 (en) | 2009-07-22 |
BRPI0621947A2 (pt) | 2011-10-18 |
IL198168A0 (en) | 2009-12-24 |
MX2009003771A (es) | 2009-07-22 |
JP2010505949A (ja) | 2010-02-25 |
AU2006349402A1 (en) | 2008-04-17 |
KR20090113243A (ko) | 2009-10-29 |
JP5422388B2 (ja) | 2014-02-19 |
WO2008045060A1 (en) | 2008-04-17 |
CA2652981A1 (en) | 2008-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2652981C (en) | Robust sustained release formulations | |
US20080085304A1 (en) | Robust sustained release formulations | |
CA2644992C (en) | Ethanol-resistant sustained release formulations | |
AU2002337686B2 (en) | Opioid formulations having reduced potential for abuse | |
CA2913368C (en) | Abuse deterrent immediate release formulation | |
US8501160B2 (en) | Crush-resistant oxycodone tablets intended for preventing accidental misuse and unlawful diversion | |
AU2002337686A1 (en) | Opioid formulations having reduced potential for abuse | |
WO2003004033A1 (en) | Sustained release formulations of oxymorphone | |
WO2008027350A2 (en) | Acetaminophen pharmaceutical compositions | |
US20080085305A1 (en) | Robust sustained release formulations of oxymorphone | |
AU2006349472A1 (en) | Robust sustained release formulations of oxymorphone and methods of use thereof | |
US20080085303A1 (en) | Robust sustained release formulations of oxymorphone and methods of use thereof | |
AU2006349471A1 (en) | Robust sustained release formulations of oxymorphone | |
KR20090065543A (ko) | 옥시모르폰의 강건한 서방형 제제 및 이의 제조 및 사용 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20201013 |